The high-mobility group A1a/signal transducer and activator of transcription-3 axis: An achilles heel for hematopoietic malignancies?

Cancer Research

Volumn 68, Issue 24, 2008, Pages 10121-10127

  Hillion, Joelle ^a,b   Dhara, Surajit ^a,b,c,d   Sumter, Takita Felder ^a,b,c,k   Mukherjee, Mita ^a,b,c   Di Cello, Francescopaolo ^a,b   Belton, Amy ^a,b   Turkson, James ^f,g   Jaganathan, Souyma ^f,g   Cheng, Linzhao ^d   Ye, Zhaohui ^d   Jove, Richard ^h   Aplan, Peter ⁱ   Lin, Ying Wei ^i,l   Wertzler, Kelsey ^j   Reeves, Ray ^j   Elbahlouh, Ossama ^a,b,c   Kowalski, Jeanne ^e   Bhattacharya, Raka ^a,b,c   Resar, Linda M S ^a,b,c,d,e  

^a Division of Hematology   (United States)

^b Department of Medicine ^*  (United States)

^c Pediatric Genetics   (United States)

^d Oncology   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Biomolecular Science Center   (United States)

^g UNIVERSITY OF CENTRAL FLORIDA   (United States)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j WASHINGTON STATE UNIVERSITY   (United States)

^k WINTHROP UNIVERSITY   (United States)

^l MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP A1A PROTEIN; MESSENGER RNA; STAT3 PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL MOTILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE ACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOMA; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOLOGIC NEOPLASMS; HMGA1A PROTEIN; HUMANS; MICE; PROMOTER REGIONS, GENETIC; RATS; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION; UP-REGULATION;

EID: 57749115895     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2121     Document Type: Article

References (22)

1. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007;7:899-910.
2. Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene 2001;277:63-81.
3. Wood LJ, Mukherjee M, Dolde CE, et al. HMG-I/Y: a new c-Myc target gene and potential oncogene. Mol Cell Biol 2000;20:5490-502.
4. Wood LJ, Maher JF, Bunton TE, Resar LMS. The oncogenic properties of the HMG-I gene family. Cancer Res 2000;60:4256-61.
5. Reeves R, Edberg DD, Ying L. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol 2001;21:575-94.
6. Takaha N, Resar LM, Vindivich D, Coffey DS. High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. Prostate 2004;60:160-7.
7. Scala S, Portella G, Fedele M, Chiapetta G, Fusco A. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci U S A 2000;85:6047-51.
8. Xu Y, Sumter Felder T, Bhattacharya R, et al. The HMG-I oncogene causes highly penetrant, metastatic lymphoid malignancy in transgenic mice and is overexpressed in human lymphoid malignancy. Cancer Res 2004;64:3371-75.
9. Fedele M, Pentimalli F, Baldassarre G, et al. Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 2005;24:3427-35.
10. Tesfaye A, Di Cello F, Hillion J, et al. The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res 2007;67:3998-4004.
11. Munshi N, Yie Y, Merika M, et al. The IFN-β enhancer: a paradigm for understanding activation and repression of inducible gene expression. Cold Spring Harb Symp Quant Biol 1999;64:149-59.
12. Treff NR, Dement GA, Adair JE, et al. Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells. Oncogene 2004;23:8557-62.
13. Treff NR, Pouchnik D, Dement GA, Britt RL, Reeves R. High-mobility group A1a protein regulates Ras/ERK signaling in MCF-7 human breast cancer cells. Oncogene 2004;23:777-85.
14. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998;18:2553-58.
15. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
16. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
17. Turkson J, Zhang S, Palmer J, et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 2004;3:1533-42.
18. Varga T, Aplan PD. Chromosomal aberrations induced by double strand DNA breaks. DNA Repair 2005;4:1038-46.
19. Kato K, Nomoto M, Izumi H, et al. Structure and functional analysis of the human STAT3 gene promoter: alteration of chromatin structure as a possible mechanism for the up-regulation in cisplatin-resistant cells. Biochem Biophys Acta 2000;1493:91-100.
20. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentivirus vectors. Science 2002;295:868-72.
21. Di Cello F, Hillion J, Kowalski J, et al. Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts. Mol Cancer Ther 2008;7:2090-5.
22. Karhadkar SS, Bova SG, Abdallah N, et al. Hedgehog signaling in prostate regeneration, neoplasia, and metastasis. Nature 2004;431:701-12.